

February 27, 2023

US Bank, N.A. One Federal Street - 3rd Floor Boston, MA 02110

RE: Officers Certificate for Dartmouth-Hitchcock Obligated Group (D-HOG) relating to the quarterly filing for December 31, 2022.

Issues Including:

Cheshire Medical Center Series 2012
Mary Hitchcock Memorial Hospital Series 2014A/B
Mary Hitchcock Memorial Hospital Series 2016B
Dartmouth-Hitchcock Health Series 2017A/B
Dartmouth-Hitchcock Health Series 2018A/B
Alice Peck Day Memorial Hospital Series 2018C
Dartmouth-Hitchcock Health Series 2019A
Dartmouth-Hitchcock Health Series 2020A

Taxable Notes Payable

Dartmouth-Hitchcock Health TD Bank, National Association

I hereby certify that the Obligated Group's quarterly report for the quarter ended December 31, 2022 constitutes the quarterly financial information required by the Continuing Disclosure Agreement. I further certify that the information complies with the Continuing Disclosure Agreements relating to the above-referenced issues. US Bank shall be entitled to rely on this certificate.

If you have further questions about this matter please do not hesitate to call.

Sincerely,

Daniel P. Jantzen
Chief Financial Officer

Dartmouth-Hitchcock Health



Dartmouth-Hitchcock Health Management's Discussion and Analysis For the Six Months Ended December 31, 2022

The following management discussion and analysis was prepared for Dartmouth-Hitchcock Health's (the "System" or "D-HH") Consolidated Balance Sheets and Statements of Operations and Changes in Net Assets without Donor Restrictions, which include the activity of all members that are part of the System. As of December 31, 2022, the System comprises the following entities: Dartmouth-Hitchcock Health and Subsidiaries ("Parent"), Dartmouth-Hitchcock Clinic and Subsidiaries ("DHC"), Mary Hitchcock Memorial Hospital and Subsidiaries ("MHMH"), (DHC and MHMH together are referred to as "D-H"), The New London Hospital Association ("NLH"), Windsor Hospital Corporation (d/b/a Mt. Ascutney Hospital and Health Center) and Subsidiaries ("MAHHC"), The Cheshire Medical Center and Subsidiaries ("Cheshire"), Alice Peck Day Memorial Hospital and Subsidiary ("APD"), and the Visiting Nurse Association and Hospice of Vermont and New Hampshire Inc. and Subsidiaries ("VNH").

ATTENTION

This document is dated as of December 31, 2022, and reflects financial statements as of that date. Readers are cautioned not to assume that any information has been updated beyond the dated date unless expressly so stated. Any information referencing events after the dated date is effective only as of the date stated. We expressly disclaim any duty to provide an update of any information contained in this document. The information contained in this document includes certain information provided on a voluntary basis by the System. The System may, in its sole discretion, omit such information provided herein on a voluntary basis from its future continuing disclosure filings. The System does not hereby undertake to provide any such voluntary information in the future or to update any such voluntary information in the future.

The information contained in this document may include "forward looking statements" by using forward looking words such as "may," "will," "should," "expect(s)," "believe(s)," "anticipate(s)," "estimate(s)," or others. You are cautioned that forward-looking statements are subject to a variety of uncertainties that could cause actual results to differ from the projected results. Those risks and uncertainties include general economic and business conditions, receipt of funding grants, and various other factors, which are beyond our control. Because we cannot predict all factors that may affect future decisions, actions, events, or financial circumstances, what actually happens may be different from what we include in forward looking statements.




For the Six Months Ending December 31, 2022 Compared to the Same Period of the Prior Year

As described more fully below, D-HH incurred a \$78.0 million (5.3%) operating loss for the six months ending December 31, 2022, as the System continued to be impacted by external financial pressures and challenges stemming from the highly complex national health care environment in which it is operating. In the midst of this environment, D-HH is focused on two critically important issues.

First and foremost, is the ongoing challenge of staffing clinical operations to the fullest extent possible in order to fulfill the organization's mission and to continue to provide the high quality, high value care our patients need and expect. Given the national labor shortage, particularly in the health care sector, this has resulted in significant labor premiums as the organization has reverted to high cost travelers to ensure adequate staffing. The financial impact of this challenge has been further exacerbated by a lack of available post-acute care beds in the region, largely driven by skilled nursing and inpatient rehab facilities who are grappling with their own workforce shortages. Reduced post-acute bed availability has resulted in increased lengths of stay in member hospitals due to an inability to discharge patients in a timely manner thereby adding pressure to an already capacity constrained inpatient system.

In the midst of this backdrop, D-HH is focused on improving its financial performance to ensure that it can continue to meet the needs of the communities it serves and to maintain the financial profile that has allowed it to be successful. To that end, in November 2022, D-HH initiated a formal Performance Improvement Plan with a goal of achieving break-even monthly performance during FY24. All levels of the organization are keenly focused on this objective and we expect that the improvement will come from a combination of initiatives that increase volumes and revenues and decrease expenses, as well as from additional inpatient capacity being constructed on the Dartmouth Hitchcock Medical Center (DHMC) campus as described below. D-HH has engaged two nationally recognized consulting firms to assist with this work.

D-HH will be in a stronger position to meet excess patient demand when it opens its newly constructed Patient Pavilion at DHMC in May 2023. The opening of the Pavilion will bring 64 new, state-of-the-art patient beds to the System's flagship academic campus in Lebanon. At the same time, 36 existing patient beds will be closed for renovation, resulting in a net initial increase of 28 beds. Over time, the remaining beds will open as renovations are completed. As a reminder, funding




of the \$150 million Pavilion was secured with the issuance of D-HH's Series 2020A bonds in January of 2020. The project is expected to be completed on time and within budget.

COVID-19 has clearly presented D-HH with ongoing financial challenges. While we have faced and overcome financial challenges in the past and have confidence in our ability to do so again, we must acknowledge the difficult and national nature of this unique situation. The scale and macroeconomic effects of some of these issues is unprecedented. At the same time the Performance Improvement Plan is further developed and executed, D-HH continues to actively take action to mitigate the financial impact of COVID-19 and its lingering aftereffects. We continue to actively reevaluate, adapt, and add to these mitigating tactics as the situation on the ground changes. Recruitment and retention of high-quality staff remains one of the organization's highest priorities. Additionally, we are curtailing capital spending as much as possible to improve liquidity. We are committed to achieving sustainable financial results, but cannot predict how the lingering aftereffects of the pandemic will effect operations or economic conditions in the future.

As can be seen from the chart below, all of these factors have put significant pressure on D-HH's operating margin.

DH-H Monthly Operating Margin (excluding Federal Stimulus Funds)



Fortunately, the majority of the \$299 million in cumulative operating losses incurred from March 1, 2020, through June 30, 2022, have been offset by \$250.5 million in cumulative stimulus funds.



Operating Results

For the six months ending December 31, 2022, the D-HH System incurred a \$78.0 million (5.3%) consolidated Operating Loss, an amount that was \$65.0 million greater than the Operating Loss incurred for the same period of the prior year when stimulus funds are excluded. D-HH received \$1.8 million and \$70.4 million of stimulus funds for the six months ending December 31, 2022 and 2021, respectively.

Revenue

D-HH generated \$1.48 billion of Total Operating Revenue and Other Support (excluding stimulus funds) for the six months ending December 31, 2022, an increase of \$113.1 million (8.2%) when compared to the same period of the prior year. Net Patient Service Revenue (excluding NH Disproportionate Share Hospital revenue commonly referred to as DSH) increased by \$36.7 million (3.4%) due to year over year volume growth and increases in contracted payment rates. Other Operating Revenue (excluding stimulus funds) increased by \$71.1 million (33.8%) as compared to the prior year due to growth driven by the ongoing successful expansion of D-HH's Contract and Specialty Pharmacy businesses.

During the six months ending December 31, 2022, System surgical cases grew by 8.0% over the prior year while discharges and ambulatory appointments increased by 1.5% and 0.7%, respectively. As previously noted, the System continues to grapple with inpatient capacity constraints as well as staff vacancies that have been partially mitigated by the use of high cost travelers.

Update on Disproportionate Share Hospital Revenue ("DSH")

There are four D-HH hospital members in New Hampshire that are eligible to receive disproportionate share hospital ("DSH") payments based on the large number of Medicaid and uninsured patients to whom those D-HH members provide health care services. Pursuant to a settlement agreement with the State of New Hampshire, D-HH hospital members in New Hampshire recognized \$38.0 million and \$33.8 million in DSH revenue for the six months ending December 31, 2022 and 2021, respectively. DSH revenue is accrued and included in revenue on a pro rata basis throughout the year.

Expenses

D-HH's consolidated operating expenses for the six months ending December 31, 2022, were \$1.56 billion, \$178.1 million (12.8%) higher than for the same period of the prior fiscal year. Consistent with previous quarters, the primary drivers of expense growth were in the categories of compensation, medications and purchased services and other. Due to the relative size of D-H, it was the primary source of many of the System's expense increases. D-H's total workforce costs (salaries and employee benefits) were \$75.7 million (11.6%) higher than the same period of the prior fiscal



year, driven by increased rates of pay year-over-year, including premium pay associated with high cost travelers. D-H's medication and medical supply costs grew by \$42.2 million (15.1%) over the same period of the prior fiscal year, a result of expanded pharmacy services and higher acuity procedural volumes (with higher associated supply costs). Higher than planned medication and medical supply costs were appropriately matched by increased revenue and margin. Medical supply expense also included purchases related to growth in COVID testing.

Changes in Unrestricted Cash and Investments / Liquidity Update

Operating losses, an increased expense base, and working capital changes for the six months ending December 31, 2022, combined to lower D-HH's Days Cash on Hand by 25 days, from 149 days to 124 days, excluding the impact of temporary CARES Act funds. This represents a 2 day decrease from the 126 Days Cash on Hand level at the end of the previous quarter, September 30, 2022.

D-HH unrestricted cash and investments totaled \$1.05 billion as of December 31, 2022. This amount no longer includes any CMS prepayment advances or payroll tax deferrals as they have all been repaid (the final \$72.7 million of these temporary funds received under the CARES Act were repaid during the six months ending December 31, 2022). Excluding all temporary CARES Act funds, D-HH's unrestricted cash and investments have decreased by \$96.9 million during the last six months. Operating margin losses (\$78.0 million) are the key driver of the decline, partially offset by improved investment performance during the last quarter, which brought investment income slightly positive for the fiscal year at \$5.7 million. The remaining \$24.6 million decline is made up primarily of working capital changes and capital spend.

As we have noted previously, in February 2019, D-HH transferred \$132.0 million from cash and invested into a high quality and short duration fixed income portfolio, which we refer to as the Intermediate Fund. The purpose of this fund is to provide D-HH with a contingent source of liquidity from high quality fixed income investments. As of December 31, 2022, the Intermediate Fund has a market value of \$126.7 million and is included on the Balance Sheet under "Assets limited as to use."

As of December 31, 2022, D-HH had short-term liquidity of \$279.7 million in immediately available cash and short-term, high quality fixed-income investments, as follows:



Cash and cash equivalents \$102.0 million
D-HH Intermediate Fund: \$126.7 million
Line of Credit Availability: \$51.0 million
Total short-term liquidity: \$279.7 million

Subsequent to the end of the quarter, D-HH increased its Line of Credit capacity from \$75 million to \$100 million.

Annual Debt Service Coverage Ratio for the Six Months Ended December 31, 2022

The presentation of the annual debt service coverage ratio for the six months ended December 31, 2022, is included in this filing. As of December 31, 2022, D-HH's annual debt service coverage ratio was -1.71x, primarily resulting from the operating losses recognized for the fiscal year to date. We are reviewing every option available and taking all necessary steps in order to improve our financial performance and achieve an annual debt service coverage ratio over 1.1x. As mentioned above, D-HH has engaged two nationally recognized consulting firms to assist us with our Performance Improvement Plan, with the goal to improve annual operating margin results.

D-HH Major Capital Projects

DHMC Patient Pavilion – Lebanon, NH (\$150M budget):

The DHMC Patient Pavilion project is on budget and on schedule to open in early May 2023. There are no critical building materials, furniture and medical equipment availability issues at this time. Only final construction building finishes. system commissioning and punch list items remain to be completed. It is anticipated that the



certificate of occupancy will be issued in early March 2023 allowing staff to fully occupy the new Pavilion for final clinical equipment installations. Staff training and patient simulation are well underway to ensure a smooth opening for patients and staff.

DARTMOUTH-HITCHCOCK OBLIGATED GROUP

QUARTERLY REPORT

For the Period Ended December 31, 2022

Unaudited

In accordance with the Master Trust Indenture and Continuing Disclosure Agreements, Dartmouth-Hitchcock Obligated Group (D-HOG) presents the financial results of Dartmouth-Hitchcock Health and Subsidiaries ("D-HH") for the quarter and year to date periods ended December 31, 2022 and 2021, and the Consolidated Balance Sheets as of December 31, 2022 and the fiscal year ended June 30, 2022.

<u>D-HH is comprised of the following entities:</u> Dartmouth-Hitchcock Health, Dartmouth-Hitchcock Clinic and Subsidiaries, Mary Hitchcock Memorial Hospital and Subsidiaries, The New London Hospital Association, Windsor Hospital Corporation (d/b/a Mt. Ascutney Hospital and Health Center) and Subsidiaries, The Cheshire Medical Center and Subsidiaries, Alice Peck Day Memorial Hospital and Subsidiary, and the Visiting Nurse and Hospice of Vermont and New Hampshire, Inc. and Subsidiaries.

<u>D-HOG members include:</u> Dartmouth-Hitchcock Health, Dartmouth-Hitchcock Clinic, Mary Hitchcock Memorial Hospital, The New London Hospital Association, Windsor Hospital Corporation (d/b/a Mt. Ascutney Hospital and Health Center), The Cheshire Medical Center, and Alice Peck Day Memorial Hospital.

Dartmouth-Hitchcock Obligated Group Quarterly Report December 31, 2022 Unaudited

Table of Contents

	Page
Dartmouth-Hitchcock Health and Subsidiaries Financial Information	
Consolidated Balance Sheets	1
Consolidated Statements of Operations and Changes in Net Assets	
without Donor Restrictions	
For the Quarters Ended December 31, 2022 and 2021	2
For the Six Months Ended December 31, 2022 and 2021	3
Consolidated Summary Statement of Unrestricted Liquidity	4
Consolidated Summary Annual Debt Service Coverage Ratio	5
Consolidated Utilization Statistics	6

Dartmouth-Hitchcock Health and Subsidiaries Consolidated Balance Sheets

(000's **Omitted**)

	nber 31, 2022 Inaudited	June 30, 2022 Audited		
Assets				
Current assets				
Cash and cash equivalents	\$ 101,980	\$	191,929	
Patient accounts receivable, net	241,010		251,250	
Prepaid expenses and other current assets	217,863		169,133	
Total current assets	560,853		612,312	
Assets limited as to use	1,048,421		1,181,094	
Other investments for restricted activities	174,761		175,116	
Property, plant and equipment, net	783,416		764,840	
Right of use assets, net	57,745		58,925	
Other assets	 170,527		172,163	
Total assets	\$ 2,795,723	\$	2,964,450	
Liabilities and Net Assets				
Current liabilities				
Current portion of long-term debt	\$ 15,237	\$	6,596	
Current portion of right-of-use obligations	11,608		11,319	
Line of credit	24,000		-	
Current portion of liability for other post-retirement plan benefits	3,500		3,500	
Accounts payable and accrued expenses	151,426		156,572	
Accrued compensation and related benefits	140,710		190,560	
Estimated third-party settlements	82,387		134,898	
Total current liabilities	 428,868		503,445	
Long-term debt, excluding current portion	1,100,427		1,117,288	
Long-term right-of-use obligations, excluding current portion	47,453		48,824	
Insurance deposits and related liabilities	78,422		78,391	
Liability for pension and other post-retirement plan benefits, excluding current portion	235,957		228,606	
Other liabilities	153,709		154,096	
Total liabilities	2,044,836		2,130,650	
Net assets				
Net assets without donor restrictions	548,402		634,297	
Net assets with donor restrictions	202,485		199,503	
Total net assets	750,887		833,800	
Total liabilities and net assets	\$ 2,795,723	\$	2,964,450	

Dartmouth-Hitchcock Health and Subsidiaries Consolidated Statements of Operations and Changes in Net Assets without Donor Restrictions For the Quarters Ended December 31, 2022 and 2021 (000's Omitted)

	Quarter-to-date				
	December 31, 2022 Unaudited			December 31, 2021 Unaudited	
Operating revenue and other support	-	_		_	
Net patient service revenue	\$	585,601	\$	565,574	
Contracted revenue		20,422		18,892	
Other operating revenue		148,161		178,952	
Net assets released from restrictions		3,400		4,197	
Total operating revenue and other support		757,584		767,615	
Operating expenses					
Salaries		358,381		316,950	
Employee benefits		86,834		83,466	
Medical supplies and medications		176,178		156,159	
Purchased services and other		120,285		95,887	
Medicaid enhancement tax		21,169		20,457	
Depreciation and amortization		23,220		21,678	
Interest		8,137		7,952	
Total operating expenses		794,204		702,549	
Operating (loss) margin		(36,620)		65,066	
Non-operating gains					
Investment gains		39,721		39,171	
Other, net		(7,547)		490	
Total non-operating gains, net		32,174		39,661	
(Deficiency) excess of revenue over expenses		(4,446)		104,727	
Net assets without donor restrictions					
Net assets released from restrictions		54		747	
Change in funded status of pension and other post-retirement benefits		114		30	
Other changes in net assets		-		(23)	
(Decrease) increase in net assets without donor restrictions	\$	(4,278)	\$	105,481	

Dartmouth-Hitchcock Health and Subsidiaries Consolidated Statements of Operations and Changes in Net Assets without Donor Restrictions For the Six Months Ended December 31, 2022 and 2021 (000's Omitted)

	Year-to-Date			
		mber 31, 2022 Unaudited	December 31, 2021 Unaudited	
Operating revenue and other support				
Net patient service revenue	\$	1,155,429	\$	1,114,608
Contracted revenue		39,648		38,052
Other operating revenue		283,269		280,733
Net assets released from restrictions		7,881		8,300
Total operating revenue and other support		1,486,227		1,441,693
Operating expenses				
Salaries		708,401		621,452
Employee benefits		166,155		162,038
Medical supplies and medications		360,901		315,074
Purchased services and other		225,863		187,801
Medicaid enhancement tax		42,337		40,696
Depreciation and amortization		44,403		42,968
Interest		16,203		16,143
Total operating expenses		1,564,263		1,386,172
Operating (loss) margin		(78,036)		55,521
Non-operating (losses) gains				
Investment gains		5,684		45,575
Other, net		(14,125)		2,909
Total non-operating (losses) gains, net		(8,441)		48,484
(Deficiency) excess of revenue over expenses		(86,477)		104,005
Net assets without donor restrictions				
Net assets released from restrictions		468		1,713
Change in funded status of pension and other post-retirement benefits		114		30
Other changes in net assets		-		(23)
(Decrease) increase in net assets without donor restrictions	\$	(85,895)	\$	105,725

Dartmouth-Hitchcock Health and Subsidiaries Consolidated Summary Statement of Unrestricted Liquidity For the Six Months Ended December 31, 2022 and 2021 and the Year Ended June 30, 2022 (000's Omitted)

	December 31, 2022 Unaudited		June 30, 2022 Audited		,		nber 31, 2021 Unaudited
Cash and cash equivalents (1)	\$	77,980	\$	191,929	\$ 281,086		
Assets whose use is limited by Board designation (2)		944,560		1,024,175	 1,194,712		
Total unrestricted cash and investments	\$	1,022,540	\$	1,216,104	\$ 1,475,798		
Days cash on hand *		124		158	 202		

^{*} Unrestricted Days Cash on Hand excluding the Medicare Advanced Payments and Payroll Tax Relief in June 2022 and December 2021 would be 149 and 180, respectively. As of December 2022 all relief payments were repaid, in full.

(1) Reconciliation of Cash and cash equivalents to Consolidated Balance Sheet:

December 31, 2022		Jun	June 30, 2022		December 31, 2021	
\$	101,980	\$	191,929	\$	281,086	
	(24,000)		-		-	
\$	77,980	\$	191,929	\$	281,086	
	\$ \$	(24,000)	\$ 101,980 \$ (24,000)	\$ 101,980 \$ 191,929 (24,000) -	\$ 101,980 \$ 191,929 \$ (24,000) -	

(2) Reconciliation of Assets whose use is limited to Consolidated Balance Sheet:

	Dece	ember 31, 2022 June 30, 2022		December 31, 2021		
Assets limited as to use (as presented on the						
Consolidated Balance Sheet)	\$	1,048,421	\$	1,181,094	\$	1,388,953
Less: Held by trustee under bond indenture agreement		(46,339)		(99,397)		(137,002)
Less: Held by captive insurance company		(57,522)		(57,522)		(57,239)
Assets whose use is limited included in the						
Consolidated Statement of Unrestricted Liquidity	\$	944,560	\$	1,024,175	\$	1,194,712

Dartmouth-Hitchcock Health and Subsidiaries Consolidated Summary Annual Debt Service Coverage Ratio For the Period Ended December 31, 2022 (000's Omitted)

Unaudited

Debt Service Coverage Ratio (Covenant >1.10x)

Deficiency of revenues over expenses Subtract: net unrealized gains on investments	\$	(86,477) (2,590)
Subtract. Het unrealized gams on investments		(2,370)
Excluded from expenses:		
Depreciation and amortization		44,403
Interest expense on long-term indebtedness included in operating expenses		16,203
Interest expense on long-term indebtedness included in non-operating gains	=	1,857
Aggregate Income Available for Debt Service	\$	(26,604)
Debt Service	\$	15,550
Coverage of Debt Service	<u>-</u>	-1.71

This information is subject to change without notice, may be affected by future events and actions that may be outside the control of D-HH, and D-HH does not undertake to supplement this filing for future events or circumstances.

Dartmouth-Hitchcock Health and Subsidiaries Consolidated Utilization Statistics For the Six Months Ended December 31, 2022 and 2021

Statistics	December 31, 2022 Unaudited	December 31, 2021 Unaudited	% of Prior Year
Licensed Beds	650	650	100.0%
Total Discharges	18,544	18,278	101.5%
Total Patient Days	94,702	89,991	105.2%
Occupancy (as a percentage of staffed beds)	86.0%	81.5%	105.5%
Average Length of Stay (days)	5.1	4.9	104.1%
Total Appointments	805,926	800,386	100.7%